Cell therapy weekly: immunotherapy effectively treats melanoma caused by CDKN2A mutation
This week in cell therapy: The global CAR T-cell therapy market has been forecasted to grow 63.15%, a new immunotherapy demonstrates effective treatment of a heredity melanoma and a clinical trial of stem cell therapy for eye injuries receives US$5.25 million grant.
Please sign in or register for FREE
Sign in to RegMedNet
Not yet a member? Become a member FREE to:
- Get unlimited access to ALL CONTENT
- Read selected articles from journals such as Regenerative Medicine FREE
- Receive a weekly email roundup of the latest news and expert opinions
Did you know?
Your RegMedNet account also gives you access to communities on drug discovery, real-world evidence and 3D printing in medicine. Find out more>>